NASDAQ:PRME
Prime Medicine, Inc.
Prime Medicine, Inc.'s revenue grew 55.3% in fiscal 2025 to $4.6M while operating margin rose to −4498.1%. Free cash flow was −$167.1M, −3607.4% of revenue, and the diluted share count rose 25.4%.Summary generated from Prime Medicine, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.6M
Revenue growth+55.3%
Revenue, 5-yr CAGR−2.3%
Gross marginn/a
Operating margin−4498.1%
Net margin−4342.4%
ROICn/a
Return on equity−146.8%
Debt / equityn/a
Free cash flow−$167.1M
FCF margin−3607.4%
Share count change+25.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3 | 5 |
| Operating income | −84 | −117 | −205 | −202 | −208 |
| Net income | −165 | −122 | −198 | −196 | −201 |
| Free cash flow | −38 | −148 | −174 | −130 | −167 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KOther events
Jul 8, 2026 - 4Insider transaction report
Jun 8, 2026 - 4Insider transaction report
Jun 8, 2026 - 8-KResults of a shareholder vote
Jun 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026